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Immunotherapy approaches currently make their way into the clinics to improve the 
outcome of standard radiochemotherapy (RCT). The programed cell death receptor 
ligand 1 (PD-L1) is one possible target that, upon blockade, allows T cell-dependent 
antitumor immune responses to be executed. To date, it is unclear which RCT protocol 
and which fractionation scheme leads to increased PD-L1 expression and thereby ren-
ders blockade of this immune suppressive pathway reasonable. We therefore investi-
gated the impact of radiotherapy (RT), chemotherapy (CT), and RCT on PD-L1 surface 
expression on tumor cells of tumor entities with differing somatic mutation prevalence. 
Murine melanoma (B16-F10), glioblastoma (GL261-luc2), and colorectal (CT26) tumor 
cells were treated with dacarbazine, temozolomide, and a combination of irinotecan, 
oxaliplatin, and fluorouracil, respectively. Additionally, they were irradiated with a single 
dose [10 Gray (Gy)] or hypo-fractionated (2 × 5 Gy), respectively, norm-fractionated 
(5 × 2 Gy) radiation protocols were used. PD-L1 surface and intracellular interferon 
(IFN)-gamma expression was measured by flow cytometry, and IL-6 release was 
determined by ELISA. Furthermore, tumor cell death was monitored by AnnexinV-
FITC/7-AAD staining. For first in vivo analyses, the B16-F10 mouse melanoma model 
was chosen. In B16-F10 and GL261-luc2 cells, particularly norm-fractionated and 
hypo-fractionated radiation led to a significant increase of surface PD-L1, which could 
not be observed in CT26 cells. Furthermore, PD-L1 expression is more pronounced on 
vital tumor cells and goes along with increased levels of IFN-gamma in the tumor cells. 
In melanoma cells CT was the main trigger for IL-6 release, while in glioblastoma cells 
it was norm-fractionated RT. In vivo, fractionated RT only in combination with dacar-
bazine induced PD-L1 expression on melanoma cells. Our results suggest a tumor 
cell-mediated upregulation of PD-L1 expression following in particular chemoradiation 
that is not only dependent on the somatic mutation prevalence of the tumor entity.
Keywords: fractionated radiotherapy, immunotherapy, checkpoint inhibitor, PD-l1, iFn-gamma, il-6, melanoma, 
glioblastoma
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inTrODUcTiOn
A promising new cancer treatment strategy is combining classical 
radiochemotherapy (RCT, chemoradiation) with immunotherapy 
(IT). Even it is known since long time that RCT does not induce 
complete immune suppression and that besides temporarily 
restricted leukopenia and granulocytopenia, the remaining 
immune cells preserve their function (1), only in the recent 
years preclinical and clinical research focused on combination 
of RCT with IT (2). As certain chemotherapeutic agents such as 
anthracyclines (3), also ionizing radiation is capable of rendering 
the tumor cell and its microenvironment immunogenic by induc-
ing the upregulation of activation markers for immune cells and 
death receptors on tumor cells and by further inducing the release 
of danger signals and cytokines (4–6).
However, besides these immune-stimulating properties of 
radiation, it can also induce the upregulation of immune sup-
pressive molecules. The programed cell death receptor ligand 1 
(PD-L1, CD274, or B7-H1) is one prominent example for this. 
Under normal physiological conditions, PD-L1 is constitutively 
expressed on immune cells, including dendritic cells (DCs), 
as well as on non-hematopoietic cells (7) and helps to main-
tain self-tolerance. Upon binding to its inhibitory receptor, 
programed death receptor 1 (PD-1) (8), T cells are impaired 
(9). Many tumor entities show a constant PD-L1 surface 
expression and thereby evade immune surveillance (7, 10). The 
pro-inflammatory cytokine interferon (IFN)-gamma has been 
shown to induce upregulation of PD-L1 on the surface of tumor 
cells (11).
Therefore, blocking either the immune checkpoint protein 
PD-1 or its ligands PD-L1 and/or PD-L2 are new anticancer 
treatment strategies that have already been shown to be success-
ful (12). Durable responses occurred in 30–35% of patients with 
advanced melanoma (13–15), and consecutively many clinical 
and preclinical studies for other tumor entities such as lung (16), 
breast (17, 18), and bladder (19) were initiated.
In particular, to exploit the radiation-induced increased 
endogenous antitumor immune responses, the increased expres-
sion of PD-L1 on tumor cells or infiltrating immune cells has to 
be counteracted by blocking the PD-1/PD-L1 pathway (20). For 
this, knowledge about expression of PD-L1 on tumor cells after in 
particular RCT is mandatory to adapt multimodal therapies for 
the most beneficial induction of antitumor immunity.
Of note is that targeting PD-L1 is not equally successful in 
every patient and should have PD-L1 surface expression on 
the tumor cells as prerequisite (21). Studies examining PD-L1 
expression in murine tumor models have already shown that 
radiation can induce an upregulation of PD-L1 on tumor cells 
as unwanted side effect. It is mostly mediated by IFN-gamma-
producing T  cells (22). Furthermore, chemoradiation led to 
increased PD-1 expression on CD4+ T cells in the peripheral 
blood of patients with human papillomavirus-related oro-
pharyngeal cancer (23).
However, only little is known which RCT protocol induces 
immunogenic tumor cell death and further leads to increased 
PD-L1 expression on tumor cells of a distinct tumor entity and 
thereby renders blockade of the PD-1/PD-L1 pathway reasonable. 
We therefore investigated the effect of tumor entity-related RCT 
schemes on the induction of cell death and concomitant PD-L1 
expression on viable and apoptotic tumor cells. The latter are 
immune suppressive since they expose phosphatidylserine (24). 
This could be further enhanced by additional expression of 
PD-L1, which is again counterproductive for antitumor immune 
responses.
The somatic mutation prevalence of tumor cells is highly 
connected with the tumor cells immunogenicity. Mutations 
might lead to the generation of neoantigens against which an 
immune response is started (25). Radiotherapy (RT) further 
contributes to the generation of neoantigens, and neoantigen-
specific CD8+ T  cell responses have been shown to go along 
with tumor regression (26). Since melanoma has the highest 
somatic mutation prevalence it does respond very well to IT. We 
therefore focused in our preclinical examinations on this tumor 
entity and compared it with one displaying only intermediate 
somatic mutation prevalence, namely colorectal cancer (27). 
Additionally, glioblastoma cells were included to get hints about 
RCT-induced modulation of the immunological tumor cell 
phenotype of a tumor entity located at an immune-privileged 
organ, namely the brain.
MaTerials anD MeThODs
cell culture and reagents
Established murine melanoma (B16-F10, ATCC, USA), glio-
blastoma (GL261-luc2, Caliper, USA), and colorectal carcinoma 
(CT26, ATCC, USA) cell lines were used. B16-F10 and CT26 
cells were maintained in RPMI 1640 medium (Sigma, USA), sup-
plemented with 10% heat-inactivated FCS, 100 U/ml penicillin, 
and 100 µg/ml streptomycin (Gibco, USA). GL261-luc2 cells were 
cultured in high glucose Dulbecco’s Modified Eagle’s Medium 
(Gibco, USA) supplemented with heat-inactivated 10% FCS 
(Biochrom, Germany) and 0.5% geneticin (Gibco, USA). Cells 
were grown in cell culture flasks (Greiner BioOne, Germany) in 
a humidified chamber at 37°C and 5% CO2. All cell lines were 
tested to be free of mycoplasma contamination. Irinotecan, 
oxaliplatin, and fluorouracil were purchased as ready-to-use 
infusions. Temozolomide (TMZ, Sigma-Aldrich, USA) was dis-
solved at a stock concentration of 100mM in dimethylsulfoxide 
(Roth, Germany) and stored at −20°C. Dacarbazine (DTIC, 
Sigma-Aldrich, USA) was dissolved in culture medium before 
use. Chemotherapeutics were diluted in the respective medium 
before cell treatment. As a positive control for PD-L1 induction 
(0.5 ng/ml), recombinant murine interferon-gamma (rmIFN-γ, 
R&D Systems, USA) was administered to otherwise non-treated 
cell cultures.
Treatment of Tumor cell lines
Cells were seeded at a density of 20,000–25,000 B16-F10 cells, 
30,000 CT26 cells, and 100,000 GL261-luc2 cells per 25 cm2. After 
resting overnight, tumor cells were subjected to chemotherapeutic 
treatments and radiation. In brief, B16-F10 cells were treated with 
a single dose of 250µM DTIC on day 1, GL261-luc2 cells were 
treated with 20µM TMZ every other day for 5 days, and CT26 
FigUre 1 | radiation and chemotherapy (cT) treatment scheme for the cell lines B16-F10 (a), gl261-luc2 (B), and cT26 (c). After seeding, cells rested 
overnight. B16-F10 cells were treated with a single dose of 250µM DTIC on day 1, GL261-luc2 cells with 20µM temozolomide every other day for 5 days, and CT26 
cells with single doses of 10 µg/ml irinotecan, 10 µg/ml oxaliplatin, and 400 ng/ml 5-fluorouracil. After CT, cells of all cell lines were irradiated with either a single 
dose of 10 Gray (Gy) on day 5, 2 × 5 Gy on days 3 and 5 or 5 × 2 Gy. Cells were analyzed 24 or 48 h after the last treatment.
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cells were incubated with single doses of 10  µg/ml irinotecan, 
10 µg/ml oxaliplatin, and 400 ng/ml 5-fluorouracil for 4 h, before 
chemotherapy (CT) was washed off using Dulbecco’s phosphate-
buffered saline (Gibco, Germany) and cells were cultured in fresh 
medium.
After CT, cells were irradiated using an X-ray generator 
(120  kV, 22.7  mA, variable time; GE Inspection Technologies, 
Germany) with either a single dose of 10  Gray (Gy) on day 5, 
hypo-fractionated 2 × 5 Gy on days 3 and 5 or norm-fractionated 
5 × 2 Gy RT (Figure 1).
cell Death Determination and PD-l1 
surface expression of Tumor cells
About 24 and 48  h after the last irradiation, tumor cells were 
harvested for analyses by flow cytometry. For cell death detection 
and analysis of PD-L1 or PD-L2 surface expression, 0.5–1 × 105 
tumor cells were blocked with Fc Block (anti-CD16/32 antibodies, 
Affymetrix, USA), stained with 7-Aminoactinomycin D (7-AAD 
Biolegend, USA), AnnexinV-FITC (AxV, Life Technologies 
and Sigma-Aldrich, USA), and anti-PD-L1-PE-Cyanine7 
(Affymetrix, USA) or anti-PD-L2-APC (Biolegend, USA) for 
30  min at 4°C in the dark and analyzed using flow cytometry 
(Gallios, Beckman Coulter, USA). Before use, the anti-PD-L1 
(clone MIH5, dilution 125 ng/ml) and anti-PD-L2-APC (clone 
TY25, 1/100, Biolegend, USA) antibodies were titrated, and the 
isotype control for every condition was subtracted from the 
measured PD-L1 or PD-L2 mean fluorescence intensity. Cells 
negative for AnnexinV-FITC and 7-AAD (AxV−/7-AAD−) were 
identified as vital, cells positive for AxV but negative for 7-AAD 
(AxV+/7-AAD−) as apoptotic and cells positive for 7-AAD 
(7-AAD+) as necrotic.
Measurement of intracellular iFn-gamma
For intracellular analysis of IFN-gamma, the Cytofix/Cytoperm-
Kit (BD Biosciences, USA) protocol was followed. In brief, cells 
were incubated with the protein transport inhibitor brefeldin 
A for 4 h at 37°C and 5% CO2 to support intracellular cytokine 
accumulation, and they were then trypsinized and counted. 
A total of 2 × 105 cells were afterward fixed and permeabilized. 
Subsequently, cells were stained with an anti-IFN-gamma-
PE-Cyanine7 antibody (XMG1.2, BD Biosciences, USA) and 
analyzed by flow cytometry.
Measurement of extracellular il-6
IL-6 was determined in the supernatants of the tumor cells by 
ELISA according to the manufacturer’s instructions (IL-6 ELISA 
kit from BioLegend, USA).
c57Bl/6-B16-F10 Mouse  
Melanoma Model
C57BL/6 mice (Janvier, Germany) were maintained in a SPF 
facility under sterile atmosphere at the animal facility of the 
Friedrich-Alexander-Universität Erlangen-Nürnberg (Franz-
Penzoldt-Center). Here, the animals can also be kept after 
chemoradiation. The animal procedures have been approved by 
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the “Regierung of Mittelfranken” and were conducted in accord-
ance with the guidelines of Federation of European Laboratory 
Animal Science Associations (FELASA).
About 8- to 10-week-old female C57BL/6 mice were used 
for the B16-F10 melanoma model: 1  ×  106 B16-F10 cells 
(ATCC, USA) were re-suspended in 200 µl Ringer’s solution and 
injected subcutaneously into the right flank of the mice on day 0. 
The tumor volume was monitored using a digital caliper at the 
given time points and calculated using the following formula: 
volume (mm3) = 0.5 × width2 (mm2) × length (mm) (28).
The tumor-bearing mice were then randomly assigned to 
the different treatment groups (group 1: untreated controls, 
group 2: fractionated RT, and group 3: fractionated RT plus 
DTIC). Local irradiation of the mice was done as established 
and published before by our group (28). At day 8, 9, and 10 
after tumor induction, local RT with 2 Gy was performed. At 
day 8 and 10, DTIC (2 mg/mouse) was injected i.p., 2 h after 
irradiation.
For investigation of PD-L1 expression on B16-F10 tumor 
cells, the tumors were dissected on day 13 after tumor induc-
tion, and single cell suspensions were prepared using a tumor 
dissociation kit (Miltenyi Biotec, Germany). For separation of 
dead cells and cell debris, an easycoll-solution based (Biochrom, 
Germany) density gradient centrifugation was performed. 
Unspecific binding sites were blocked using anti-CD16/32 
(eBioscience, USA) antibodies, and cells were then stained for 
30 min at 4°C with fluorescence labeled antibodies: CD45-FITC 
(eBioScience, USA), PD-L1-PE-Cy7 (eBioscience, USA), and 
PD-L1-BV421 (BioLegend, USA). Afterward, multicolor flow 
cytometry was performed using the Gallios Flow Cytometer 
(Beckman Coulter Inc.).
statistical analyses
The arithmetic mean of replicates, as calculated by flow analysis 
software Kaluza 1.2 and 1.3 (Beckman Coulter, USA), is depicted. 
The software Prism 5 (graph pad, USA) was used for statistics. For 
all analyses, one-tailed Mann–Whitney U test was used, unless 
stated otherwise. Results were considered statistically significant 
for *p < 0.05, **p < 0.01, and ***p < 0.001.
resUlTs
in Particular Fractionated rT increases 
PD-l1 surface expression on Vital 
B16-F10 Melanoma cells
The B16-F10 melanoma cells proved to be highly resistant against 
radiation, since 24  h after the respective treatments only few 
tumor cells died via apoptosis or necrosis. After 48 h, in particular 
DTIC plus fractionated RT with 2 × 5 Gy or 5 × 2 Gy induced 
apoptosis and necrosis, but still over 50% of the melanoma cells 
were vital (Figure 2A).
To determine whether PD-L1 expression is dependent on 
the induction of cell death, its surface expression on vital and 
apoptotic tumor cells (Figures 2B,C) was compared. All tumor 
cells do express PD-L1 and in particular on vital B16-F10 cells, 
norm-fractionated and hypo-fractionated RT resulted in the 
highest increase of surface expression of PD-L1.
Although to a lesser extent but still significant when compared 
to mock-treated cells, single dose irradiation with 10 Gy or DTIC 
treatment also led to an increase in PD-L1 surface expression 
(Figures  2B,C). Combination of DTIC and RT resulted in 
similar expression levels of PD-L1 compared to only RT-treated 
cells at an early time point (24 h) after treatment (Figure 2B). 
Representative histograms of the increased surface expression 
of PD-L1 of B16-F10 melanoma cells after chemoradiation 
(RCT) are shown in the Figure S1A in Supplementary Material. 
Furthermore, a significant increase of PD-L1 expression was also 
observed on already dying tumor cells after radiation or chemo-
radiation (Figure 2C).
in Particular Fractionated rT and TMZ 
increase PD-l1 surface expression on 
Vital glioblastoma gl261-luc2 cells
The percentage of apoptotic as well as necrotic murine glio-
blastoma cells (GL261-luc2) was increased by fractionated RT 
(2 × 5 Gy and 5 × 2 Gy) or the combination of a single 10 Gy 
irradiation with TMZ 48  h after the treatments (Figure  3A). 
Furthermore, a slight, but not significant enhancement of dying 
or dead cells could be observed when combining TMZ with 
fractionated RT.
Regarding PD-L1 surface expression, similar to B16-F10 
cells, vital tumor cells displayed the highest level, in particular 
after fractionated RT and/or treatment with TMZ (Figure 3B). 
Representative histograms of the increased surface expression 
of PD-L1 of GL261-luc2 cells after chemoradiation (RCT) are 
shown in the Figure S1B in Supplementary Material. Dying, 
namely apoptotic, glioblastoma cells displayed a slight, but sig-
nificant upregulation of PD-L1 expression 48 h after treatment 
with fractionated RT or chemoradiation (Figure 3C).
rT and cT have no significant impact on 
PD-l1 surface expression on colorectal 
cT26 Tumor cells
The murine colorectal tumor cells (CT26) were more sensitive to 
RT and/or CT, and higher percentages of apoptotic and necrotic 
tumor cells were induced compared to melanoma and glioblas-
toma cells (Figure 4A). While PD-L1 expression was inducible 
with recombinant IFN-gamma on the tumor cell surface, neither 
CT nor the tested RT protocols did significantly increase PD-L1 
surface expression on vital and apoptotic colorectal tumor cells, 
respectively (Figures 4B,C).
increased intracellular iFn-gamma 
expression and increased release of il-6 
by Tumor cells after Fractionated rT and 
chemoradiation
The increased surface expression of PD-L1 on melanoma 
(Figure 2) and glioblastoma cells (Figure 3), particularly after 
fractionated RT, was independent of contact of the tumor cells 
FigUre 2 | cell death and programed cell death receptor ligand 1 (PD-l1) surface expression of B16-F10 melanoma cells after radiation and/or 
chemotherapy. The analyses were performed 24 and 48 h after single and multimodal treatments with the chemotherapeutic agent DTIC, differently fractionated 
radiotherapy, or radiochemotherapy. Cell death was determined by flow cytometry; vital cells (white) are defined as AxV−/7-AAD−, apoptotic cells (gray) as 
AxV−/7-AAD+, and necrotic ones (dark gray) as 7-AAD+ (a). PD-L1 surface expression was determined on vital (B) and apoptotic (c) cells by staining with 
anti-PD-L1 antibody and consecutive analysis by flow cytometry. DTIC was used at a concentration of 250 µM and recombinant murine interferon-gamma (0.5 ng/
ml) served as a positive control (a–c). Joint data of three independent experiments, each performed in triplicates, are presented as mean ± SEM and analyzed by 
one-tailed Mann–Whitney U test as calculated via Graph Pad Prism. Each treatment was compared to the control (*p < 0.05; **p < 0.01; ***p < 0.001).
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with IFN-gamma-producing T cells and may therefore be 
induced by a tumor cell-dependent mechanism. We therefore 
analyzed the intracellular IFN-gamma expression as well as 
the release of IL-6 by B16-F10 and GL261-luc2 cells after 
norm-fractionated radiation, chemotherapeutic treatment, and 
chemoradiation.
An increased expression of IFN-gamma in melanoma cells 
after in particular radiation and chemoradiation was observed. 
In glioblastoma cells, IFN-gamma was increased after treatment 
with TMZ, fractionated RT, and chemoradiation (Figure  5). 
This parallels with the observed PD-L1 surface expression 
(Figure  3). Representative histograms of the increased 
expression of IFN-gamma of B16-F10 and GL261-luc2 cells 
after radiation and/or CT are displayed in the Figure S2 in 
Supplementary Material.
In melanoma cells DTIC was the main trigger to induce release 
of IL-6, in particular 48 h after treatment (Figure 6A). In contrast, 
in glioblastoma cells norm-fractionated radiation resulted in the 
highest extracellular concentration of IL-6 (Figure 6B).
Fractionated rT Plus DTic Treatment 
induces PD-l1 surface expression on 
Melanoma cells In Vivo
For first clues, whether an upregulation of PD-L1 expression 
does also occur in vivo, the syngenic B16-F10-C57/BL7 ectopic 
mouse model was chosen (28). For this, B16-F10 tumor-bearing 
mice were treated with fractionated RT with a clinically relevant 
dose of 2  Gy or in combination with DTIC administration. 
Fractionated RT as well as fractionated RT in combination with 
FigUre 3 | cell death and programed cell death receptor ligand 1 (PD-l1) surface expression of gl261-luc2 glioblastoma cells after radiation and/or 
chemotherapy. The analyses were performed 24 and 48 h after single and multimodal treatments with the chemotherapeutic agent temozolomide (TMZ), differently 
fractionated radiotherapy, or radiochemotherapy. Cell death was determined by flow cytometry; vital cells (white) are defined as AxV−/7-AAD−, apoptotic cells (gray) 
as AxV−/7-AAD+, and necrotic ones (dark gray) as 7-AAD+ (a). PD-L1 surface expression was determined on vital (B) and apoptotic (c) cells by staining with 
anti-PD-L1 antibody and consecutive analysis by flow cytometry. TMZ was used at a concentration of 20µM and recombinant murine interferon-gamma (0.5 ng/ml) 
served as a positive control (a–c). Joint data of three independent experiments, each performed in triplicates, are presented as mean ± SEM and analyzed by 
one-tailed Mann–Whitney U test as calculated via Graph Pad Prism. Each treatment was compared to the control (*p < 0.05; **p < 0.01; ***p < 0.001).
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DTIC did reduce tumor growth on a short term (Figure 7A). To 
investigate the PD-L1 expression on the melanoma cell surface, 
single cell suspensions of the tumor cells were prepared and 
B16-F10 cells were determined as CD45− cells to distinguish 
them from infiltrating immune cells (CD45+ cells). Analyses by 
flow cytometry revealed that fractionated RT did not lead to an 
increased PD-L1 expression, but combination of fractionated RT 
and DTIC resulted in significant increased expression of PD-L1 
in vivo (Figure 7B).
DiscUssiOn
Several studies have shown a relation between positive response 
to therapy with immune checkpoint inhibitors and PD-L1 
expression (13, 29–31). As such, the PD-1/PD-L1 axis has 
been regarded as a potential target in tumor tissues. Therefore, 
identifying whether and how RT or, clinically more relevant, 
chemoradiation directly results in increased PD-L1 expression 
is mandatory for optimized multimodal therapies (32). Current 
data indicate that in particular IFN-gamma, which is secreted by 
tumor-infiltrating T cells, is responsible for increased expression 
of PD-L1 on tumor cells (11, 22, 33). The knowledge about direct 
tumor cell-dependent upregulation of PD-L1 expression upon 
exposure to RT and/or CT is scarce.
Furthermore, data considering the effect of different fractiona-
tion protocols of RT on induction or attenuation of antitumor 
immune responses are controversial. On the one hand, high sin-
gle doses were shown to result in improved immunological tumor 
control compared to hyper-fractionated RT (34, 35). On the other 
hand, e.g., anti-CTLA-4-mediated immune responses were only 
observed when combined with fractionated RT (5 ×  6  Gy) in 
murine tumor models (36). We therefore examined the impact of 
single dose (1 × 10 Gy), hypo-fractionated (2 × 5 Gy), and norm-
fractionated (5 × 2 Gy) RT on PD-L1 expression of melanoma, 
FigUre 4 | cell death and PD-l1 surface expression of cT26 colorectal cancer cells after radiation and/or chemotherapy (cT). The analyses were 
performed 24 and 48 h after single and multimodal treatments with CT consisting of 10 µg/ml irinotecan, 10 µg/ml oxaliplatin, and 400 ng/ml 5-fluorouracil, 
differently fractionated radiotherapy, or radiochemotherapy. Cell death was determined by flow cytometry; vital cells (white) are defined as AxV−/7-AAD−, apoptotic 
cells (gray) as AxV−/7-AAD+, and necrotic ones (dark gray) as 7-AAD+ (a). PD-L1 surface expression was determined on vital (B) and apoptotic (c) cells by staining 
with anti-PD-L1 antibody and consecutive analysis by flow cytometry. Recombinant murine interferon-gamma (0.5 ng/ml) served as a positive control (a–c). Joint 
data of three independent experiments, each performed in triplicates, are presented as mean ± SEM and analyzed by one-tailed Mann–Whitney U test as calculated 
via Graph Pad Prism. Each treatment was compared to the control (*p < 0.05; **p < 0.01; ***p < 0.001).
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glioblastoma, and colorectal cancer cells. Since in the clinics CT 
is given in addition to RT, we further focused on single and com-
bined treatment with the respective chemotherapeutic agents. We 
here show for the first time that CT, namely DTIC and TMZ, 
significantly enhanced PD-L1 cell surface expression on B16-F10 
and GL261-luc2, respectively, albeit the upregulation occurred on 
a low level (Figures 2 and 3).
Notably, norm-fractionated (5 × 2 Gy) and hypo-fractionated 
(2 ×  5  Gy) irradiation induced the highest PD-L1 expression 
levels. It has to be stressed that this is primarily an undesired 
immunosuppressive side effect of RT and therefore should entail 
addition of IT with anti-PD-L1 antibodies. Of note is that the 
increased expression of PD-L1 on the tumor cell surface was solely 
dependent on the tumor cells alone and therefore calls for a tumor 
cell-dependent effect, since all in vitro analyses were carried out 
in the absence of any immune cells. We revealed an increased 
expression of intracellular IFN-gamma following in particular 
chemoradiation in melanoma cells and after TMZ treatment, 
RT, or RCT in glioblastoma cells, respectively (Figure  5). Just 
recently, it has been demonstrated that an increased IL-6 expres-
sion is in particular observed in PD-L1-expressing human CD68+ 
macrophages compared to PD-L1 low expressing ones (37). We 
therefore also analyzed IL-6 as possible further intrinsic tumor 
cell trigger for regulating the expression of PD-L1 after radiation 
and chemoradiation. The data indicate that in melanoma IL-6 is 
mainly induced by CT and in glioblastoma by norm-fractionated 
RT. Detailed pathway analyses on the tumor cell intrinsic triggers 
for increased expression of immune checkpoints are currently on 
the way in our lab.
One has to further stress that in preclinical model systems 
a concerted view is mandatory. While in cell culture RT was 
sufficient to induce PD-L1 upregulation, the in vivo melanoma 
model showed no significant induction of PD-L1 expression 
after fractionated RT. However, additional treatment with DTIC 
FigUre 6 | il-6 release after norm-fractionated radiation and/or 
chemotherapy (cT). Supernatants of B16-F10 melanoma (a) and 
GL261-luc2 glioblastoma cells (B) were analyzed for the concentration of 
IL-6 by ELISA after treatment with either CT with DTIC or temozolomide, 
5 × 2 Gy norm-fractionated radiotherapy, or chemoradiation. Two 
independent experiments each conducted in technical duplicates were 
performed. Data are presented as mean ± SEM and analyzed by one-tailed 
Mann–Whitney U test as calculated in Graph Pad Prism. Each treatment was 
compared to the control (*p < 0.05; **p < 0.01; ***p < 0.001).FigUre 5 | intracellular interferon (iFn)-gamma levels after norm-
fractionated radiation and/or chemotherapy (cT). B16-F10 melanoma 
(a) and GL261-luc2 glioblastoma cells (B) were analyzed for intracellular 
IFN-gamma expression after treatment with either CT with DTIC or 
temozolomide, 5 × 2 Gy norm-fractionated radiotherapy, or chemoradiation. 
Data of two independent experiments, each performed in triplicates, are 
presented as mean ± SEM and analyzed by one-tailed Mann–Whitney U test 
as calculated in Graph Pad Prism. Each treatment was compared to the 
control (*p < 0.05; **p < 0.01).
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enhanced the PD-L1 surface level significantly (Figure  7). 
Thus, we strongly suggest careful in vivo investigations on the 
matter of different RT schemes and PD-L1 induction to define 
most beneficial combinations of radioimmunotherapy for the 
clinics (32).
We further showed that PD-L1 upregulation especially occurs 
on vital tumor cells and that it was dependent on the tumor entity 
(Figures 2–4). CT26 colorectal tumor cells did not respond to 
irradiation with increased PD-L1 expression, even though PD-L1 
was inducible upon stimulation with IFN-gamma (Figure 4). This 
suggests that in distinct tumor entities immune cell-mediated 
upregulation of PD-L1 expression on tumor cells is predominant, 
while in others such as melanoma and glioblastoma self-regula-
tory mechanisms could be dominant. The tumor cell lines used 
in this study are originated from different tissues, especially with 
regard to CT26, derived from a mucosal, immunological tissue 
(38). Here, immune cells might be responsible for upregulation 
of PD-L1 on the tumor cells. In contrast, glioblastoma is found 
in a rather immune-privileged area, whereas the skin tissue from 
which melanoma develops is a relevant immunological barrier. 
Therefore, tumor cell-dependent mechanisms, independent of 
immune cells, might be predominant in these cases.
The observed increased PD-L1 expression on apoptotic 
melanoma and apoptotic glioblastoma cells after chemoradiation 
additionally calls for combination with agents targeting the PD-1/
PD-L1 pathway to overcome the strong immune suppressive 
effects exerted by apoptotic cells per se. They inhibit antitumor 
immune responses in manifold ways (39).
Moreover, a tumor can only develop by accumulation of many 
mutations, and it therefore seems reasonable that every tumor 
entity and every individual tumor will have different mutations 
that may result in different cell signaling events (27). Especially, 
melanoma is at high risk of developing mutations due to its 
exposure to sun-derived UV-light, which has been suggested to 
play a key role in the susceptibility to anti-PD-1 or anti-PD-L1 
treatment (40). Furthermore, among the three examined tumor 
entities, melanoma is the one with the highest mutational load 
with a median of 13.2 mutations per Mb, followed by approxi-
mately 3.2 in colorectal cancer, and 0.9 in GBM (27). Targeting of 
PD-1 might be even more efficient than PD-L1, since PD-L2 also 
binds to PD-1 and in some tumor types PD-L2 expression is more 
closely linked to IFN-gamma expression and PD-1 signaling than 
PD-L1 (41). We therefore also checked for the impact of RT, CT, 
or RCT on increased PD-L2 expression but did not observe it in 
B16-F10 and GL261-luc2 tumor cells (data not shown).
FigUre 7 | In vivo growth and PD-l1 surface expression of B16-F10 tumors after fractionated irradiation and in combination with DTic treatment. 
Growth (a) and PD-L1 surface expression (B) of B16-F10 tumors in wild-type C57BL/6 mice are displayed. The tumors were initiated on day 0, left untreated or 
were locally irradiated on day 8, 9, and 10 with the clinically relevant dose of 2 Gray using a linear accelerator. An additional group of mice received DTIC (2 mg/
mouse) 2 h after the irradiation at day 8 and 10. For determination of tumor growth (a) an electronic caliper was used (n ≥ 8 mice/group; data are presented as 
mean ± SEM). PD-L1 surface expression on the tumor cells (each dot represents the values obtained from an individual tumor of a single mouse; the mean value is 
displayed as line) (B) was analyzed by flow cytometry at day 13. Statistics was analyzed by one-tailed Mann–Whitney U test as calculated via Graph Pad Prism.
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To summarize, the induction of PD-L1 expression by ion-
izing irradiation or chemoradiation is dependent on multiple 
factors such as the individual genetic background, signaling 
cascades, environment of the tumor, general somatic mutation 
prevalence, and therefore cannot be generalized. From this, it 
can be concluded that an anti-PD-L1 therapy concurrent to the 
classical RT or chemoradiation might not be beneficial in every 
case, since PD-L1 expression is not the cause of immunosuppres-
sion and consecutive tumor cell immune escape in all patients 
and/or tumor entities. It additionally remains unclear which 
time point is best for adding immune checkpoint blockade to 
RCT (4). Our data depict that in dependence on the tumor 
entity and time after treatment, the surface expression of PD-L1 
differs (Figures  2–4) and is partially linked with IFN-gamma 
expression and IL-6 release (Figures 5 and 6). The key aim of 
the presented study was to analyze for the first time the impact 
of in particular chemoradiation on increase of PD-L1 surface 
expression on tumor cells in the absence of further immune 
cells. This will presumably give strong hints for the designing of 
multimodal therapies consisting of RCT with immune check-
point inhibitors in the future (42).
In a preclinical tumor mouse model, Dovedi et  al. sug-
gested an antibody application on the first or last day of RT, 
but not as late as 7 days after the last treatment (22). Due to 
the hypothesis that immune cells need some time after therapy 
to get activated in the periphery and infiltrate into the tumor 
tissue (43) and the fact that PD-L1 expression needs to be 
induced in tumor cells first, it can be assumed that application 
of an anti-PD-L1 treatment can be slightly delayed to classical 
therapy start within a small timeframe. This assumption and 
its consequence for CD8+ T cell responses needs to be further 
explored in clinical trials and side effects such as autoimmune 
reactions will additionally require closely matched monitoring 
of the treated patients (44).
aUThOr cOnTriBUTiOns
AD performed together with MS most of the practical work, 
drafted and wrote the manuscript together with UG. MB car-
ried out parts of the practical work and helped to draft the 
manuscript. MH contributed to the design of the work and the 
final writing of the manuscript. RF contributed to the design of 
the work. BF contributed to assay establishments, performed 
the in vivo experiments together with AD, and did analysis and 
interpretation of the data together with UG and AD. UG drafted 
and designed the study, drafted the manuscript, and wrote it 
together with AD and MS.
FUnDing
This work was in part funded by the Bavarian Equal 
Opportunities Sponsorship—Förderung von Frauen in 
Forschung und Lehre (FFL)—Promoting Equal Opportunities 
for Women in Research and Teaching, and by the German 
Federal Ministry of Education and Research (GREWIS, 
02NUK017G). We further acknowledge the support by the 
German Research Foundation and the Friedrich-Alexander-
Universität Erlangen-Nürnberg within the funding program 
Open Access Publishing.
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found 
online at http://journal.frontiersin.org/article/10.3389/fimmu. 
2016.00610/full#supplementary-material.
FigUre s1 | Programed cell death receptor ligand 1 (PD-l1) surface 
expression of B16-F10 melanoma and gl261-luc2 glioblastoma cells 
after chemoradiation. The analyses of the increase of PD-L1 surface 
expression on B16-F10 melanoma (a) and GL261-luc2 glioblastoma cells  
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(B) were performed 24 h after chemoradiation (RCT) with 10 Gray (Gy), 
5 × 2 Gy, or 2 × 5 Gy and DTIC at a concentration of 250 µM. PD-L1 surface 
expression was determined on vital cells by staining with anti-PD-L1 
antibody and consecutive analysis by flow cytometry. Representative 
histograms of one out of three experiments each performed in triplicates  
are displayed.
FigUre s2 | interferon (iFn)-gamma expression after norm-fractionated 
radiation and/or chemotherapy (cT). The analyses by flow cytometry of the 
increase of intracellular IFN-gamma expression in B16-F10 melanoma (a) and 
GL261-luc2 glioblastoma cells (B) were performed 24 h after norm-fractionated 
radiation and/or CT treatment. Representative histograms of one out of two 
experiments each performed in triplicates are displayed.
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